198 related articles for article (PubMed ID: 28741507)
1. mTOR Signaling Confers Resistance to Targeted Cancer Drugs.
Guri Y; Hall MN
Trends Cancer; 2016 Nov; 2(11):688-697. PubMed ID: 28741507
[TBL] [Abstract][Full Text] [Related]
2. Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer.
Evangelisti C; Chiarini F; Paganelli F; Marmiroli S; Martelli AM
Biochim Biophys Acta Mol Cell Res; 2020 Apr; 1867(4):118635. PubMed ID: 31884070
[TBL] [Abstract][Full Text] [Related]
3. [mTOR inhibitor].
Muro K
Gan To Kagaku Ryoho; 2011 Jan; 38(1):7-11. PubMed ID: 21368454
[TBL] [Abstract][Full Text] [Related]
4. Role of mTOR Signaling in Tumor Microenvironment: An Overview.
Conciatori F; Bazzichetto C; Falcone I; Pilotto S; Bria E; Cognetti F; Milella M; Ciuffreda L
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30126252
[TBL] [Abstract][Full Text] [Related]
5. [mTOR complexes -- molecular spiders in molecular networks].
Kopper L; Tímár J
Magy Onkol; 2011 Nov; 55(4):287-94. PubMed ID: 22128312
[TBL] [Abstract][Full Text] [Related]
6. Targeting autophagy to overcome drug resistance in cancer therapy.
Kumar A; Singh UK; Chaudhary A
Future Med Chem; 2015 Aug; 7(12):1535-42. PubMed ID: 26334206
[TBL] [Abstract][Full Text] [Related]
7. mTOR signaling pathway and mTOR inhibitors in cancer therapy.
Gomez-Pinillos A; Ferrari AC
Hematol Oncol Clin North Am; 2012 Jun; 26(3):483-505, vii. PubMed ID: 22520976
[TBL] [Abstract][Full Text] [Related]
8. Correlation between telomerase and mTOR pathway in cancer stem cells.
Dogan F; Biray Avci C
Gene; 2018 Jan; 641():235-239. PubMed ID: 29074462
[TBL] [Abstract][Full Text] [Related]
9. mTOR inhibitors in cancer therapy.
Zaytseva YY; Valentino JD; Gulhati P; Evers BM
Cancer Lett; 2012 Jun; 319(1):1-7. PubMed ID: 22261336
[TBL] [Abstract][Full Text] [Related]
10. Translational Landscape of mTOR Signaling in Integrating Cues Between Cancer and Tumor Microenvironment.
Bazzichetto C; Conciatori F; Falcone I; Ciuffreda L
Adv Exp Med Biol; 2020; 1223():69-80. PubMed ID: 32030685
[TBL] [Abstract][Full Text] [Related]
11. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
12. mTOR: Role in cancer, metastasis and drug resistance.
Murugan AK
Semin Cancer Biol; 2019 Dec; 59():92-111. PubMed ID: 31408724
[TBL] [Abstract][Full Text] [Related]
13. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
14. The mTOR pathway in lung cancer and implications for therapy and biomarker analysis.
Ekman S; Wynes MW; Hirsch FR
J Thorac Oncol; 2012 Jun; 7(6):947-53. PubMed ID: 22588151
[TBL] [Abstract][Full Text] [Related]
15. Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway.
Wilks ST
Breast; 2015 Oct; 24(5):548-55. PubMed ID: 26187798
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.
McCubrey JA; Steelman LS; Kempf CR; Chappell WH; Abrams SL; Stivala F; Malaponte G; Nicoletti F; Libra M; Bäsecke J; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Cocco L; Martelli AM
J Cell Physiol; 2011 Nov; 226(11):2762-81. PubMed ID: 21302297
[TBL] [Abstract][Full Text] [Related]
17. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
18. [PI3K-AKT-mTOR pathway: Description, therapeutic development, resistance, predictive/prognostic biomarkers and therapeutic applications for cancer].
Brotelle T; Bay JO
Bull Cancer; 2016 Jan; 103(1):18-29. PubMed ID: 26582734
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
20. mTOR and cancer: insights into a complex relationship.
Sabatini DM
Nat Rev Cancer; 2006 Sep; 6(9):729-34. PubMed ID: 16915295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]